Proven Intelligence Accelerating Next-Generation Therapies.

Executive Summary

Controlling host cell protein (HCP) impurities is a primary objective in scalable adeno-associated virus (AAV) vector manufacturing. These process-related impurities present a direct risk to program success by potentially eliciting immune responses or affecting vector stability and function. A robust manufacturing strategy involves a multi-faceted approach, combining upstream process optimization to minimize HCP expression with advanced downstream purification techniques and sensitive analytical methods for characterization and clearance. This ensures the final AAV product meets the stringent purity and quality standards required for Investigational Medicinal Product Dossier (IMPD) submissions and progression toward clinical evaluation.

The Challenge of Host Cell Proteins in AAV Production

The purity of a viral vector preparation is directly linked to its clinical performance profile. While the AAV capsid and transgene are the intended components, the manufacturing process inevitably introduces process-related impurities, with host cell proteins representing a significant class. These proteins, derived from the production cell line, can co-purify with the vector and present considerable challenges.

The potential for immunogenicity driven by HCPs is a well-documented concern. The introduction of foreign proteins can activate both innate and adaptive immune responses. As research on viral vector-mediated immune activation has shown, even fragments of a protein can elicit a robust cellular immune response (PMID: 15823604). This principle extends to HCPs, where residual proteins can act as adjuvants or direct antigens, compromising the therapeutic outcome.

Upstream and Downstream Process Control

A tailored preclinical strategy for AAV manufacturing does not rely on a standard template. It begins with a data-driven approach to process development.

• Upstream Optimization: Control starts in the bioreactor. Modifying transfection parameters, media selection, and harvest timing can significantly reduce the overall HCP load before purification begins.

• Downstream Purification: The primary clearance of HCPs occurs during downstream processing. We utilize multi-modal chromatography steps, including affinity, ion-exchange, and size-exclusion columns, to separate the AAV capsids from contaminating proteins.

The specificity of AAV biology underscores the need for a pure product. Research identifying specific cell surface proteins as drivers for vector transport highlights how precise these interactions are (PMID: 30819613). The presence of confounding HCPs could interfere with these targeted biological mechanisms, making their effective removal a manufacturing priority.

“We started collaborating with UPenn Vector core in 2023 and the AAV vector which they manufactured laid a foundation for development of a gene therapy candidate which will enter soon preclinical studies. The key people from UPenn Vector Core joined Franklin Biolabs and our partnership transitioned without interruption from UPenn Vecor Core to Franklin Biolabs Research Vector Division. Franklin Biolabs is an essential collaborator in our AAV-vector based gene therapy candidate development and we hope to continue this collaboration for years to come.”
— Biotech Partner

Analytical Characterization for Regulatory Submissions

Demonstrating control over impurities is a cornerstone of any CMC package for an IMPD or IND submission. For HCPs, this requires phase-appropriate analytical methods. A well-qualified, process-specific HCP ELISA provides the quantitative data needed for lot release, while orthogonal methods like mass spectrometry offer deeper qualitative insights.

This analytical package provides assurance that the manufacturing process is consistent and capable of producing a high-purity vector. This level of characterization is fundamental to minimizing clinical risk and aligns with the expectations of global regulatory bodies for next-generation therapies. While Franklin Biolabs launched in 2024, our scientific leadership team’s work has contributed to a 100% successful IND rate since 2019.